SONOCO PRODUCTS COSON
SONOCO PRODUCTS CO Debt Disclosure
Debt
Details of the Company’s debt at December 31 were as follows:
| 2025 | 2024 | ||||||||||
| 364-Day term loan due December 2025 | $ | — | $ | 1,493,568 | |||||||
| Term loan due December 2026 | — | 698,167 | |||||||||
| Syndicated term loan due August 2028 | 498,320 | 497,674 | |||||||||
1.80% notes due February 2025 | — | 399,933 | |||||||||
4.45% notes due September 2026 | 498,749 | 496,869 | |||||||||
2.25% notes due February 2027 | 299,443 | 298,930 | |||||||||
4.60% notes due September 2029 | 595,694 | 594,519 | |||||||||
3.125% notes due May 2030 | 597,528 | 596,958 | |||||||||
2.85% notes due February 2032 | 496,824 | 496,302 | |||||||||
5.00% notes due September 2034 | 690,857 | 689,802 | |||||||||
5.75% notes due November 2040 | 536,314 | 536,282 | |||||||||
Other foreign denominated debt, average rate of 5.5% in 2025 and 6.0% in 2024 | 40,016 | 155,048 | |||||||||
| Finance lease obligations | 53,542 | 67,628 | |||||||||
| Other debt | 19,638 | 18,341 | |||||||||
| Total debt | $ | 4,326,925 | $ | 7,040,021 | |||||||
| Less: Notes payable and current portion of long-term debt | (537,952) | (2,054,525) | |||||||||
| Long-term debt | $ | 3,788,973 | $ | 4,985,496 | |||||||
On February 3, 2025, the Company repaid the $400,000 aggregate principal amount of its 1.80% notes upon their maturity using proceeds from the issuance of commercial paper.
On September 16, 2024, the Company entered into a credit agreement with the lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent which provides the Company with the ability to borrow up to $1,500,000 on an unsecured basis (the “364-Day Term Loan Facility”) to finance a portion of the cash consideration for the Company’s acquisition of Eviosys. The Company drew down the entire 364-Day Term Loan Facility on December 2, 2024 in connection with the consummation of the Eviosys acquisition on December 4, 2024. Borrowings under the 364-Day Term Loan Facility, became payable upon completion of the TFP divestiture. Accordingly, on April 3, 2025, the Company repaid the outstanding $1,500,000 principal amount of borrowings using a portion of the cash proceeds from the sale of TFP.
On July 12, 2024, the Company entered into a credit agreement with the lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent which provided the Company with the ability to borrow up to $700,000 on an unsecured basis (the “Term Loan Facility”) to finance a portion of the cash consideration for the Company’s acquisition of Eviosys. The Company drew down the entire Term Loan Facility on December 2, 2024 in connection with the consummation of the Eviosys acquisition on December 4, 2024. Borrowings under the Term Loan Facility became payable upon completion of the ThermoSafe divestiture. Accordingly, on November 5, 2025, the Company repaid the outstanding $700,000 principal amount of borrowings using cash proceeds from the sale of ThermoSafe and the issuance of commercial paper.
On September 19, 2024, the Company completed a registered public offering of senior unsecured notes (the “Notes”) in a combined aggregate principal amount of $1,800,000. The Notes consisted of the following:
| Principal Amount | Issuance Costs and Discounts | Net Proceeds | Interest Rate | Maturity | |||||||||||||||||||||||||
| 2026 Notes | $ | 500,000 | (3,697) | $ | 496,303 | 4.45 | % | September 1, 2026 | |||||||||||||||||||||
| 2029 Notes | 600,000 | (5,851) | 594,149 | 4.60 | % | September 1, 2029 | |||||||||||||||||||||||
| 2034 Notes | 700,000 | (10,542) | 689,458 | 5.00 | % | September 1, 2034 | |||||||||||||||||||||||
| Total | $ | 1,800,000 | $ | (20,090) | $ | 1,779,910 | |||||||||||||||||||||||
The Company used the net proceeds from the Notes, together with the borrowings under the Term Loan Facility and 364-Day Term Loan Facility and cash on hand to fund the cash consideration payable by the Company in connection with the Eviosys acquisition and to pay related fees and expenses. See Note 4 for more information.
Included in “Other foreign denominated debt” at December 31, 2024 are $73,487 of transfers of certain trade receivables of Eviosys to third-party financial institutions for which the requirements to be accounted for as true sale in accordance with the guidance under ASC 860 “Transfers and Servicing,” were not met. Additions to and settlements of these obligations during the year ended December 31, 2025 are reflected as “Proceeds from issuance of debt” and “Principal repayment of debt,” respectively, in “Net cash (used)/provided by financing activities” in the Company’s Consolidated Statements of Cash Flows. All of these obligations had been settled as of December 31, 2025.
In conjunction with the announcement of the acquisition of Eviosys, the Company entered into a commitment letter with certain financial institutions that provided for a 364-day senior unsecured bridge term loan facility (the “Bridge Loan Facility”) on June 22, 2024 in an aggregate amount of up to $4,000,000 to secure funding of the acquisition. As a result of obtaining financing for the Eviosys acquisition through the Term Loan Facility, the 364-Day Term Loan Facility, and the Notes, the Company terminated the commitments under the Bridge Loan Facility and the related commitment letter effective September 19, 2024. Fees related to the Bridge Loan Facility of $19,000 were amortized to interest expense during the year ended December 31, 2024.
On August 7, 2023, the Company entered into a credit agreement with a consortium of Farm Credit System institutions and CoBank, ACB, as Administrative Agent (the “Syndicated Term Loan Agreement”). The Syndicated Term Loan Agreement provides the Company with the ability to borrow up to $900,000 on an unsecured basis (the “Syndicated Term Loan Facility”). A total of $600,000 was drawn from the Syndicated Term Loan Facility on August 7, 2023 and used to repay the syndicated term loans that were due in December 2023 and January 2025, and to make certain capital expenditures and reimburse the Company for certain capital expenditures it had made in its operation of waste disposal facilities in rural areas. An additional $270,000 was drawn from the Syndicated Term Loan Facility on September 8, 2023 and used to partially fund the acquisition of the remaining interest in RTS Packaging and the acquisition of the Chattanooga Mill (see Note 4 for more information). Borrowings under the Syndicated Term Loan Facility, net of any prepayments, will become payable in full on August 7, 2028. During the years ended December 31, 2024 and 2023, the Company repaid $75,000 and $295,000, respectively, of the amounts drawn under the Syndicated Term Loan Facility. Borrowings under the Syndicated Term Loan Facility bear interest at a fluctuating rate per annum equal to, at the Company’s option, (i) the forward-looking SOFR term rate (“Term SOFR” and such borrowings, “Syndicated Term SOFR Loans”), (ii) a base rate set forth in the Syndicated Term Loan Agreement, or (iii) a combination thereof, plus, in each case, an applicable margin calculated based on the Company’s credit ratings and, in the of case of Syndicated Term SOFR Loans, a SOFR Adjustment (as defined in the Syndicated Term Loan Agreement) of 0.1%. The Company has designated its borrowings under the Syndicated Term Loan Facility as Syndicated Term SOFR Loans. The margin currently applicable to Syndicated Term SOFR Loans based on the Company’s credit ratings, together with the SOFR Adjustment, is 1.90%. If Term SOFR ceases to be available, the benchmark rate shall switch to Daily Simple SOFR (as defined in the Syndicated Term Loan Agreement). There is no required amortization under the Syndicated Term Loan Facility, and voluntary prepayments are permissible without penalty, subject to certain conditions pertaining to minimum notice and minimum prepayment and reduction amounts as described in the Syndicated Term Loan Agreement.
The Syndicated Term Loan Agreement contains various customary representations and warranties and affirmative and negative covenants, as more fully described in the Syndicated Term Loan Agreement. The Syndicated Term Loan Agreement also contains various customary events of default (subject to grace periods, as applicable) including, among others: nonpayment of principal, interest or fees; breach of covenant; payment default on, or acceleration under, certain other material indebtedness; inaccuracy of the representations or warranties in any material respect; bankruptcy or insolvency; inability to pay debts; certain unsatisfied judgments; certain ERISA-related events; the invalidity or unenforceability of the Syndicated Term Loan Agreement or certain other documents executed in connection therewith; and the occurrence of a change of control.
On May 3, 2024, the Company entered into an Amended and Restated Credit Agreement (the “Agreement”) to extend the maturity and make certain other changes to the terms under the Company’s existing five-year credit agreement dated June 21, 2021. The Agreement increases the commitments under the Company’s revolving credit facility by $350,000 to $1,250,000 and extends the maturity date to May 3, 2029. The Company also increased its $500,000 commercial paper program by $750,000 to $1,250,000. The revolving credit facility continues to support the commercial paper program. At December 31, 2025, the Company had no commercial paper balances outstanding; accordingly, the committed capacity available for drawdown under its revolving credit facility at December 31, 2025 was $1,250,000. Based on the pricing grid, the credit agreement for the revolving credit facility and Sonoco’s current credit ratings, any drawings are subject to the Term SOFR plus the 137.5 basis points margin.
The principal requirements of debt maturing in the next five years are:
| 2026 | 2027 | 2028 | 2029 | 2030 | |||||||||||||||||||||||||
| Debt maturities by year | $ | 537,952 | $ | 316,438 | $ | 513,555 | $ | 600,802 | $ | 602,236 | |||||||||||||||||||
As of December 31, 2025, the Company has scheduled debt maturities through the next twelve months of $537,952. At December 31, 2025, the Company had $378,398 in cash and cash equivalents on hand, and $1,250,000 in committed capacity available for drawdown under its revolving credit facility. The Company believes that these amounts, combined with expected net cash flows from operating activities, provide ample liquidity to cover debt maturities and other cash flow needs of the Company over the course of the next year.
In addition, the Company had approximately $287,325 available under unused short-term lines of credit at December 31, 2025. These short-term lines of credit are available for general corporate purposes of our subsidiaries, including working capital and hedging requirements.
Certain of the Company’s debt agreements impose restrictions with respect to the maintenance of financial ratios and the disposition of assets. The most restrictive covenants currently require the Company to maintain a minimum level of interest coverage and a minimum level of net worth, as defined in the agreements. As of December 31, 2025, the Company’s interest coverage and net worth were substantially above the minimum levels required under these covenants.Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2021 | Feb 28, 2022 | |
| 2020 | Feb 26, 2021 | |
| 2019 | Feb 28, 2020 | |
| 2018 | Feb 28, 2019 | |
| 2017 | Feb 28, 2018 | |
| 2016 | Mar 1, 2017 | |
| 2015 | Feb 29, 2016 | |
About Debt Disclosures
Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.
Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.